Philips showcases comprehensive cardiology portfolio designed to increase physician confidence and efficiency in diagnosing and treating cardiac disease at ACC/WCC 2023
March 2, 2023
- Philips Ultrasound Compact System 5500 CV adds to Philips’ cardiology portfolio bringing diagnostic quality cardiac imaging to the patient bedside
- Clinical evidence presented by leading clinical partners shows how utilization of Philips cardiology solutions improves patient care
Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing enhancements to its cardiology portfolio at the Annual Scientific Session & Expo of the American College of Cardiology/World Congress of Cardiology event (ACC.23/WCC, March 4 – 6, New Orleans, USA). Philips’ cardiology portfolio addresses ever-increasing demand for cost-effective diagnosis, treatment, monitoring, and management of patients with heart conditions such as coronary artery disease, structural heart disease, arrhythmia, and heart failure.
Highlighted introductions to the portfolio include the company’s latest compact portable ultrasound platform – Philips Ultrasound Compact System 5500 CV, its spectral-detector based CT scanner, Philips Spectral CT 7500, and Philips Intracardiac Echocardiography Catheter – VeriSight Pro 3D ICE.
Evidence-based cardiology innovation
In line with Philips’ commitment to supporting its innovations with clinical evidence, three of the company’s clinical partners will present the results of clinical studies at ACC.23/WCC that could help inform clinical guidelines.
- Dr. Eric Secemsky, Director of Vascular Intervention at Beth Israel Deaconess Medical Center (Boston, MA, USA) will present the results of a high-quality real-world evidence study of data for over a million U.S. Medicare patients to evaluate trends in the use of, and outcomes associated with, intravascular imaging (IVI) during percutaneous coronary intervention (PCI) procedures. Philips is a leader in IVI with its intravascular ultrasound (IVUS) solutions.
- Dr. Mohamad Alkhouli, Professor of Medicine at Mayo Clinic School of Medicine (Rochester, MN, USA) will present a study on the real-world performance and safety of the Philips Intracardiac Echocardiography Catheter – VeriSight Pro 3D ICE.
- Dr. Sean Pokorney, Assistant Professor of Medicine and Member of the Duke Clinical Research Institute at Duke University School of Medicine (Durham, NC, USA) will examine the hospitalization and healthcare expenditure benefits associated with guideline driven care and early extraction of infected cardiac implantable electronic devices (CIEDs), for which Philips is the market leader in lead management devices.
All three clinical studies are part of more than 110 ongoing clinical studies that support Philips image-guided therapy solutions with clinical evidence.
Other highlighted innovations from its cardiology portfolio that Philips is showcasing at ACC.23/WCC are the company’s advanced image-guided therapy platform Philips Image-Guided Therapy System – Azurion; Philips Interventional Applications Platform – IntraSight interventional workspace; Philips IntelliSpace ECG providing fast, easy access to ECGs from almost anywhere in the medical facility; and Philips Mobile Cardiac Telemetry – MCOT ambulatory cardiac monitoring solution.
For a more complete overview with in-depth information of the Philips solutions showcased at ACC.23/WCC please see our backgrounder.
To connect with experts and learn more about Philips cardiology solutions, stop by Philips booth #338. The clinical study presentation by Dr. Mohamad Alkhouli will take place on March 4, 2023, 1:45 PM - 1:55 PM (CST) and the presentation by Dr. Sean Pokorney on March 6, 2023, 9:45 AM - 10:30 AM (CST). The presentation by Dr. Eric Secemsky is in digital-only format and can be accessed through the ACC.23/WCC eAbstracts site by registered users.
For further information, please contact:
Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Philips Intracardiac Echocardiography Catheter – VeriSight Pro
- Azurion image-guided therapy platform
- Philips Ultrasound Compact System 5500 CV
- Philips Spectral CT 7500
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release
VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi
Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release
BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa
Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release
BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe
Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release
First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann